Dr. Walters on the Safety Profile of Beti-Cel in Pediatric Transfusion-Dependent Beta-Thalassemia

Video

Mark Walters, MD, discusses the safety profile of betibeglogene autotemcel gene therapy in pediatric patients with transfusion-dependent β-thalassemia, as reported in the phase 3 Northstar-2 and Northstar-3 trials.

Mark Walters, MD, director of the Pediatric Blood and Marrow Transplant Program at UCSF Benioff Children's Hospital Oakland, discusses the safety profile of betibeglogene autotemcel (beti-cel; Zynteglo) gene therapy in pediatric patients with transfusion-dependent β-thalassemia (TDT), as reported in the phase 3 Northstar-2 and Northstar-3 trials.

All patients enrolled to these trials received myeloablative busulfan conditioning. Due to this, patients experienced complications with busulfan that were concurrent with autologous transplant, such as febrile neutropenia, mucositis, and elevated transaminase levels, Walters says. However, most of these toxicities did not reach grade 3 severity, Walters notes.

Importantly, a serious complication that was observed was veno-occlusive disease of the liver, which occurred in approximately 15% to 20% of patients, Walters explains. This complication, which can occur after busulfan is received, is caused by damage to a particular zone of the liver, leading to liver enlargement, issues with fluid retention, and even renal dysfunction, Walters concludes.

Related Videos
Paul Harmatz, MD
Mark Walters, MD
Mitchel Horwitz, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Raj Chovatiya, MD, PhD
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
© 2024 MJH Life Sciences

All rights reserved.